Free Trial

Plus Therapeutics (PSTV) News Today

Plus Therapeutics logo
$1.24 +0.07 (+5.98%)
As of 04:00 PM Eastern
Plus Therapeutics presented data on ReSPECT-LM Phase 1 trial
Plus Therapeutics to present FORESEE clinical trial summary
Plus Therapeutics subsidiary to present data on CNSide CSF Assay Platform
Plus Therapeutics Advances Radiotherapeutics in Q3 2024
A Peek at Plus Therapeutics's Future Earnings
Plus Therapeutics, SpectronRx announce manufacturing partnership
Q2 2024 Plus Therapeutics Inc Earnings Call
Plus Therapeutics reports progress in CNS cancer trial
Plus Therapeutics earnings: here's what Wall Street expects
Get Plus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.

PSTV Media Mentions By Week

PSTV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PSTV
News Sentiment

0.00

0.63

Average
Medical
News Sentiment

PSTV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PSTV Articles
This Week

0

1

PSTV Articles
Average Week

Get Plus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:PSTV) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners